Joan Perello
University Of The Balearic Islands
Palma, PM, Spain
Palma, PM, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Hexasodium Fytate (SNF472 or CSL525) Inhibits Ectopic Calcification in Various Pseudoxanthoma Elasticum and Calcinosis Cutis Animal Models.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: March 07, 2025
Hexasodium fytate for the treatment of calciphylaxis: a randomised, double-blind, phase 3, placebo-controlled trial with an open-label extension.
Journal: EClinicalMedicine
Published: April 05, 2024
Hexasodium fytate exposure-response correlations in a randomized, placebo-controlled study of patients on dialysis with cardiovascular calcification.
Journal: Frontiers in pharmacology
Published: October 24, 2023
The CALCIPHYX study: a randomized, double-blind, placebo-controlled, Phase 3 clinical trial of SNF472 for the treatment of calciphylaxis.
Journal: Clinical kidney journal
Published: April 06, 2021
Author Correction: A novel assay to measure calcification propensity: from laboratory to humans.
Journal: Scientific reports
Published: February 17, 2021
Effects of Myo-inositol Hexaphosphate (SNF472) on Bone Mineral Density in Patients Receiving Hemodialysis: An Analysis of the Randomized, Placebo-Controlled CaLIPSO Study.
Journal: Clinical journal of the American Society of Nephrology : CJASN
Published: October 28, 2020
Effects of SNF472, a Novel Inhibitor of Hydroxyapatite Crystallization in Patients Receiving Hemodialysis - Subgroup Analyses of the CALIPSO Trial.
Journal: Kidney international reports
Published: July 22, 2020
Mechanism of action of SNF472, a novel calcification inhibitor to treat vascular calcification and calciphylaxis.
Journal: British journal of pharmacology
Published: January 14, 2020
A novel assay to measure calcification propensity: from laboratory to humans.
Journal: Scientific reports
Published: November 12, 2019
Slowing Progression of Cardiovascular Calcification With SNF472 in Patients on Hemodialysis: Results of a Randomized Phase 2b Study.
Journal: Circulation
Published: November 12, 2019
Trial design and baseline characteristics of CaLIPSO: a randomized, double-blind placebo-controlled trial of SNF472 in patients receiving haemodialysis with cardiovascular calcification.
Journal: Clinical kidney journal
Published: July 22, 2019
Improvement in wound healing, pain, and quality of life after 12 weeks of SNF472 treatment: a phase 2 open-label study of patients with calciphylaxis.
Journal: Journal of nephrology
Published: March 30, 2019
Last Updated: 09/26/2026